Skip to main content
OpenTrials
Completed

NCT Number: NCT05605912

Myosuit in Incomplete Spinal Cord Injury

The Myosuit is a light-weighted lower extremity soft exosuit which provide assistance during walking. In this study the Myosuit will be tested in the home and community setting in patients with incomplete spinal cord injury.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sint Maartenskliniek

Ubbergen, Netherlands

About this study

Rationale: People with incomplete spinal cord injury (iSCI) show often impairments and limitations related to gait, which negatively affects daily life gait performance (i.e. ambulation in home and community setting) and quality of life. As a consequence of limited gait capacity, these people are likely to develop a sedentary lifestyle resulting in a vicious circle, causing a further decline in gait capacity and daily life gait performance. One of the potential options to improve gait is the use of assistive technology, such as exoskeletons or exosuits. People with iSCI have voluntary control of the leg muscles may benefit more from light-weighted exosuits which provide assistance during walking. Recently, a lower extremity soft exosuit, the Myosuit (MyoSwiss AG), has been introduced. In a small sample study, participants showed an increased gait speed when using the Myosuit compared to their baseline gait speed. Moreover, only a small number of training sessions was required to use the Myosuit. Hence, the Myosuit seems to have a high potential to increase gait capacity and daily life gait performance in people with residual gait capacity.

Objective: The study consists of two parts, randomized controlled trial (RCT) and experimental design. In the RCT, the primary objective is to test the efficacy of the Myosuit for increasing daily life gait performance in the home and community setting in people with iSCI. Secondary, the efficacy of the Myosuit program on gait capacity and its cost-utility will be investigated. Finally, the usability of the Myosuit for use in home and community setting will be evaluated. In the experimental design, we will investigate differences in gait capacity with and without wearing the Myosuit in people with iSCI, by conducting clinical tests. Secondary, differences in gait capacity measured on an instrumented treadmill with and without wearing the Myosuit will be examined.

Study design: RCT and within subject experiment.

Study population: Thirty-four people with chronic iSCI (>6 months after injury) and reduced gait capacity due to reduced knee and/or hip strength (MRC<5) will be recruited for this study. People with iSCI will be included when having an injury level of C or D on the American Spinal Injury Association Impairment Scale. In addition, participants need to have sufficient hand function to don and doff the Myosuit or they need a caregiver who is available to help the participant to use the Myosuit at home. Patients who have another (neurological) disease which can influence motor performance and/or patients who have small wounds, which can be worsened by wearing the Myosuit will be excluded. For the second objective of the experimental design, only people who are be able to walk consecutively for two minutes on a treadmill without any assistive device and without using the handrails will be included.

Intervention: RCT: The intervention group will perform training sessions with the Myosuit at the Sint Maartenskliniek. Thereafter, they will receive the Myosuit at their disposal at home and a recommendation for physical activity for six weeks. The control group will receive a program of conventional physiotherapy at the Sint Maartenskliniek. Thereafter, they receive a recommendation for physical activity for at home for six weeks.

Experimental design: Participants perform clinical tests and measurements on an instrumented treadmill with and without the Myosuit.

Measurements intervention and control group:

  • Baseline: Week 1 (T0)
  • After clinical training program at the Sint Maartenskliniek: Week 5 (T1)
  • During 6 weeks home period: Week 6, 8, 11 (T2, T3, T4)
  • After the 6 weeks home period: Week 12 (T5)

Additional measurements for the control group who receive the Myosuit intervention after the conventional program:

  • After clinical training program at the Sint Maartenskliniek: Week 16 (T6)
  • During 6 weeks home period: Week 17, 19, 22 (T7, T8, T9)
  • After the 6 weeks home period: Week 23 (T10)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • People with a stable chronic iSCI (>6 months after injury).
  • Having an injury level of C or D on the American Spinal Injury Association Impairment Scale.
  • Age ≥ 18 years.
  • Need to have sufficient hand function and standing balance to don and doff the Myosuit or they need a caregiver who is available to help the participant to use the Myosuit at home.
  • Having reduced gait capacity due to reduced knee and/or hip strength (MRC=<4).
  • Must be able to stand up from a chair without deviating to the left or right side for more than 45 degrees during the movement.
  • Can walk for 10 meter without the assistance of another person but can be assisted by assistive devices except knee orthoses.
  • People aim to improve walking distance, walking speed or gait capacity.
  • Sufficient postural control to walk independently (i.e. without assistance of a person, assistive devices are allowed).
  • For the second objective of part B of this study, only people who are be able to walk consecutively for two minutes on a treadmill without any assistive device and without using the handrails will be included

Exclusion criteria

  • Have another (neurological) disease which can influence motor performance.
  • Have wounds which can be worsened by wearing the Myosuit will be excluded.
  • Taller than 195 and smaller than 150 cm.
  • Body weight of more than 110 kg or less than 45 kg.
  • Pregnancy.
  • Insufficient mastery of the Dutch language
  • Psychiatric background.
  • Flexion contracture in knee or hip in excess of 10 degrees.
  • Knee varus malposition in excess of 10 degrees or knee valgus malposition in excess of 10 degrees.
  • Oncological spinal cord injury.
  • Unsuitable for participation according to the rehabilitation physician or researcher.

Treatment and study plan

Control

Other

Participants perform five one-hour conventional training sessions at the Sint Maartenskliniek in which they perform functional exercises. After the conventional training program, the control group will receive a recommendation for physical activity at home for six weeks.

Myosuit

Device

Participants perform five one-hour Myosuit training sessions at the Sint Maartenskliniek in which they perform functional exercises and learn to don, doff and use the device for standing, walking, climbing the stairs and sit-to-stand transitions. After the clinical Myosuit training program, participants receive the Myosuit at their disposal at home and a recommendation for physical activity at home for six weeks.

Other names: Myoswiss

Primary outcomes

  1. Change from baseline daily life gait performance to the home period as assessed by walking time per day (minutes)

    Time frame: Baseline: Week 1 (T0), During the 6-week home period: average over week 6, 8, 11 (T2, T3, T4)

    Measured by the Activ8 for 7 days. At baseline (T0) 7 days are averaged to calculate mean walking time per day. During the 6-week home period all days are averaged to calculate mean walking time per day. (RCT)

  2. Change in preferred walking speed between with and without Myosuit as assessed by the 10 meter walk test (m/s)

    Time frame: After the clinical training program: Week 5 (Myosuit intervention, T1) or week 16 (Control, T6)

    Measure for gait capacity. (experimental design)

Secondary outcomes

  1. Daily life gait performance as assessed by gait quality

    Time frame: Baseline: Week 1 (T0), During the 6-week home period: week 6 and 11 (T2, T4) and week 17 and 22 (T7, T9)

    Measured by inertial measurement units. (RCT)

  2. Change from baseline preferred walking speed at T5 as assessed by the 10 meter walk test (m/s)

    Time frame: Baseline: Week 1 (T0), After the 6-week home period: Week 12 and 23 (T5, T10)

    Measure for gait capacity. (RCT)

  3. Maximum walking speed as assessed by the 10 meter walk test (m/s)

    Time frame: Baseline: Week 1 (T0), After the 6-week home period: Week 12 and 23 (T5, T10)

    Measure for gait capacity. (RCT)

  4. Walking speed as assessed by the 6 minutes walk test (m/s)

    Time frame: Baseline: Week 1 (T0), After the 6-week home period: Week 12 and 23 (T5, T10)

    Measure for gait capacity. (RCT)

  5. Functional ambulation as assessed by the spinal cord injury functional ambulation profile (SCI-FAP)

    Time frame: Baseline: Week 1 (T0), After the 6-week home period: Week 12 and 23 (T5, T10)

    Measure for gait capacity. The SCI-FAP is composed of 7 tasks: carpet, up & go, obstacles, stairs, carry, step, and door. The highest total score is 2100. The SCI-FAP is a timed measure, a low score indicates better function. (RCT)

  6. Usability as assessed by the System Usability Scale (SUS)

    Time frame: After the clinical training program: Week 5 and 16 (T1, T6), After the 6-week home period: Week 12 and 23 (T5, T10)

    The range is between 0 and 100, with a higher score indicating better usability. (RCT)

  7. Usability as assessed by the Dutch version of the quebec user evaluation of satisfaction with assistive technology (D-QUEST)

    Time frame: After the clinical training program: Week 5 and 16 (T1, T6), After the 6-week home period: Week 12 and 23 (T5, T10)

    The range is between 1 and 5, with a higher score indicating greater satisfaction. (RCT)

  8. Quality-adjusted-life years gain assessed by EuroQol five-dimension scale questionnaire (EQ5D-5L)

    Time frame: Baseline: Week 1 (T0), After the 6-week home period: Week 12 and 23 (T5, T10)

    Measure for quality of life to investigate cost-utility. The EQ5D-5L consists of five levels with a maximum score of 1 which indicates the best health state. In addition there is a visual analogue scale with a maximum score of 100 to indicate general health status. (RCT)

  9. General and Disease Specific Self-efficacy Scale

    Time frame: Baseline: Week 1 (T0), After the 6-week home period: Week 12 and 23 (T5, T10)

    Questionnaire contains confidence in general, confidence in managing with your physical condition and confidence in walking. The range is between 0 and 160, with a higher score indicating higher confidence. (RCT)

  10. Maximum walking speed as assessed by the 10 meter walk test (m/s)

    Time frame: After the clinical training program: Week 5 and 16 (T1, T6)

    Measure for gait capacity. (experimental design)

  11. Walking speed as assessed by the 6 minutes walk test (m/s)

    Time frame: After the clinical training program: Week 5 and 16 (T1, T6)

    Measure for gait capacity. (experimental design)

  12. Preferred walking speed as assessed by walking on the GRAIL (m/s)

    Time frame: After the clinical training program: Week 5 and 16 (T1, T6)

    Measure for gait capacity. Preferred walking speed is measured during 2 minutes self-paced walking on the GRAIL. (experimental design)

  13. Step length as assessed by walking on the GRAIL

    Time frame: After the clinical training program: Week 5 and 16 (T1, T6)

    Measure for gait capacity. Step length is measured during 2 minutes walking on fixed speed on the GRAIL. (experimental design)

  14. Step time as assessed by walking on the GRAIL

    Time frame: After the clinical training program: Week 5 and 16 (T1, T6)

    Measure for gait capacity. Step time is measured during 2 minutes walking on fixed speed on the GRAIL. (experimental design)

  15. Ankle range of motion as assessed by walking on the GRAIL

    Time frame: After the clinical training program: Week 5 and 16 (T1, T6)

    Measure for gait capacity. Ankle range of motion is measured during 2 minutes walking on fixed speed on the GRAIL. (experimental design)

  16. Maximum ankle plantar flexion as assessed by walking on the GRAIL

    Time frame: After the clinical training program: Week 5 and 16 (T1, T6)

    Measure for gait capacity. Maximum ankle plantar flexion is measured during 2 minutes walking on fixed speed on the GRAIL. (experimental design)

  17. Knee range of motion as assessed by walking on the GRAIL

    Time frame: After the clinical training program: Week 5 and 16 (T1, T6)

    Measure for gait capacity. Knee range of motion is measured during 2 minutes walking on fixed speed on the GRAIL. (experimental design)

  18. Maximum knee extension as assessed by walking on the GRAIL

    Time frame: After the clinical training program: Week 5 and 16 (T1, T6)

    Measure for gait capacity. Maximum knee extension is measured during 2 minutes walking on fixed speed on the GRAIL. (experimental design)

  19. Hip range of motion as assessed by walking on the GRAIL

    Time frame: After the clinical training program: Week 5 and 16 (T1, T6)

    Measure for gait capacity. Hip range of motion is measured during 2 minutes walking on fixed speed on the GRAIL. (experimental design)

  20. Maximum hip extension as assessed by walking on the GRAIL

    Time frame: After the clinical training program: Week 5 and 16 (T1, T6)

    Measure for gait capacity. Maximum hip extension is measured during 2 minutes walking on fixed speed on the GRAIL. (experimental design)

  21. Variable error of the precision stepping task as assessed by walking on the GRAIL

    Time frame: After the clinical training program: Week 5 and 16 (T1, T6)

    Measure for gait adaptability. (experimental design)

Other outcomes

  1. Sex (man/woman)

    Time frame: Baseline: Week 1 (T0)

    Descriptive outcome measure.

  2. Age (years)

    Time frame: Baseline: Week 1 (T0)

    Descriptive outcome measure.

  3. Height (cm)

    Time frame: Baseline: Week 1 (T0)

    Descriptive outcome measure.

  4. Weight (kg)

    Time frame: Baseline: Week 1 (T0)

    Descriptive outcome measure.

  5. Body Mass Index

    Time frame: Baseline: Week 1 (T0)

    Descriptive outcome measure. Calculated with weight and height.

  6. Time since spinal cord injury (years)

    Time frame: Baseline: Week 1 (T0)

    Descriptive outcome measure.

  7. Spinal cord injury classification defined by the American Spinal Injury Association (ASIA) impairment scale (C or D)

    Time frame: Baseline: Week 1 (T0)

    Descriptive outcome measure. The scale has five classification levels (A-E), ranging from complete loss of neural function (A) in the affected area to completely normal (E).

  8. Level of spinal cord injury

    Time frame: Baseline: Week 1 (T0)

    Descriptive outcome measure. There are four sections that impact the level of spinal cord injury: cervical, thoracic, lumbar and sacral.

  9. Muscle strength as assessed by Medical Research Council (MRC) scale

    Time frame: Baseline: Week 1 (T0)

    Descriptive outcome measure. Range from 0 - 5 with higher scores indicating more strength

  10. Spasticity as assessed by Modified Ashworth Scale (MAS)

    Time frame: Baseline: Week 1 (T0)

    Descriptive outcome measure. Range from 0 - 4 with higher scores indicating more spasticity

  11. Sensory function as assessed by the American Spinal Cord Injury Association (ASIA) Impairment Scale

    Time frame: Baseline: Week 1 (T0)

    Descriptive outcome measure. Range from 0 - 2 with lower scores indicating more impaired sensory function

Sponsors and collaborators

Lead sponsor

Sint Maartenskliniek

Other

Registry information

Official study title

Efficacy of the Myosuit for Increasing Daily Life Gait Performance in the Home and Community Setting and Gait Capacity in People With Incomplete Spinal Cord Injury

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Nov 4, 2022
Registry last updated
Feb 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.